TITLE:
Management of Gestational Trophoblast Disease: An Integrative Review of National and International Guidelines
AUTHORS:
Marcela Curvêllo Beltrão, Maira de Lima Oliveira Mota, Elizabeth Bacha, Lusitania Maria de Barros, Livia Helena Gomes de Barros Brandão, Nelson Henriky Felix Mascarenhas, Tallys Leandro Barbosa da Silva, Maria Fernanda Telles Pires de Souza, Séfora Maria Fragoso Braga, Victoria de Oliveira Carmo Borges
KEYWORDS:
Guidelines, Gestational Trophoblastic Disease, Treatment
JOURNAL NAME:
Health,
Vol.14 No.12,
December
29,
2022
ABSTRACT: GTD (Gestational Trophoblastic Disease) is a pathology that encompasses benign and malignant clinical forms, affects women of childbearing age, has a variable incidence and is more frequent in developing or underdeveloped countries, colliding with the economic barrier. The frequent absence of clear protocols and guidelines for the correct diagnosis and treatment of the aforementioned pathology results in inadequate risk classification, imprecise treatment and failed post-therapeutic observation, increasing the risk of relapses, morbidity and mortality. The present study aims to compare the different national and international guidelines in the management of GTD, through an integrative review. Nine articles were selected and it was observed that the main international reference centers are agreed with the management suggested by the IFGO (International Federation of Gynecology and Obstetrics), being the conduct in the Hydatidiform Mole (HM): evacuation by suction and curettage under ultrasound guidance, followed by hCG monitoring every 1 - 2 weeks until normalized; in low-risk GTN (Gestational Trophoblastic Neoplasm): chemotherapy with methotrexate or actinomycin D, in high-risk: EMA/CO protocol, in ultra-high-risk EMA/PE, methotrexate with radiotherapy for brain metastases. All medical societies recommend the registration of these patients in GTD screening centers, endorse the use of the IFGO scoring system (2000) and recommend the surgical management of placental site trophoblastic or epithelioid tumors, as chemotherapy is less effective in these cases. The controversies are in the proper follow-up after the treatment of HM, use of ultrasound to evacuate the uterus, administration of anti-D immunoglobulin, time of oxytocin infusion and rescue regimens that can be used in cases of resistant or recurrent GTN. Establishing and complying with consistent guidelines can improve patient care, with early diagnosis of the pathology and its complications, reducing the rate of recurrence, morbidity and mortality, especially in less developed countries.